A copper-delivering compound has cleared 42% of the toxic proteins that drive Alzheimer's disease in laboratory models, restored the brain's primary waste-removal system, and improved spatial learning by nearly 44% — a preclinical finding published June 15, 2026, in ACS Chemical Neuroscience with an unusual translational advantage: the compound has already been through human safety testing for two other neurological diseases.
The study, by researchers at Monash University's Monash Institute of Pharmaceutical Sciences (MIPS), establishes a new mechanistic pathway — one that targets not the amyloid-beta proteins themselves, but the brain's impaired ability to clear them.
The Mechanism: Fixing the Brain's Clogged Drain
Alzheimer's is characterized by the accumulation of toxic amyloid-beta (Aβ) proteins. Normally, the brain flushes these through the blood-brain barrier via specialized P-glycoprotein (P-gp) transport pumps. In Alzheimer's, P-gp pump abundance declines significantly — clogging the brain's waste disposal mechanism and allowing amyloid-beta to accumulate in plaques.
Lead author Dr. Jae Pyun of MIPS explained: "This is the first study to show that Cu(ATSM) can increase the abundance of P-gp clearance pumps in an Alzheimer's model, by 24.1 percent, effectively linking the repair of the blood-brain barrier to a reduction in toxic proteins and improved cognitive function. By improving the pumps, the brain can finally clear out the trapped waste."
Cu(ATSM) — copper diacetyl bis(4-methyl-3-thiosemicarbazone) — is a small molecule that crosses the blood-brain barrier and restores P-gp pump abundance. Researchers also believe it may activate microglial immune cells that naturally break down amyloid plaques.
| Cu(ATSM) Alzheimer's Study Key Data | Detail |
| Published in | ACS Chemical Neuroscience, June 15, 2026 |
| Lead author | Dr. Jae Pyun, MIPS, Monash University |
| Senior author | Professor Joseph Nicolazzo, Director, Center for Drug Candidate Optimization |
| DOI | 10.1021/acschemneuro.6c00252 |
| Model used | APP/PS1 mouse model of familial Alzheimer's disease |
| P-gp pump increase | +24.1% |
| Amyloid-beta reduction | −42% |
| Spatial learning improvement | +44% over 56 days |
| Human safety testing | Cu(ATSM) tested in humans for Parkinson's disease and ALS |
| Approved for Alzheimer's in humans | Not yet — preclinical stage |
The Translational Advantage — Why Existing Human Safety Data Matters
The most significant aspect of this finding is that Cu(ATSM) is not a hypothetical molecule. It has already entered human clinical trials for Parkinson's disease and ALS — meaning its basic safety profile in humans is partially established. This existing data compresses the timeline from preclinical to human Alzheimer's trials meaningfully.
"The compound has strong potential to quickly transition into human clinics because it has already undergone safety evaluations for other diseases," said Professor Joseph Nicolazzo, senior author. He noted findings "provide strong support for testing the drug in people with early symptomatic Alzheimer's disease."
This study targets neurovascular clearance impairment — a mechanism increasingly recognized as a central contributor to Alzheimer's pathology, not merely a downstream consequence. Most current Alzheimer's drugs (lecanemab, donanemab) target plaques directly through antibodies; Cu(ATSM) works by restoring the brain's own clearance machinery — a fundamentally different approach.
For the 7 million+ Americans living with Alzheimer's: Cu(ATSM) has demonstrated remarkable results in a mouse model and has not been tested in humans for this indication. Human Alzheimer's trials, if they proceed, are years away from outcomes data. What this study provides is a meaningful addition to mechanistic understanding — and a compound with an expedited development path relative to drugs starting from scratch.
Frequently Asked Questions
What did the Monash University copper drug study find?
Published June 15, 2026 in ACS Chemical Neuroscience: Cu(ATSM) increased P-gp clearance pumps at the blood-brain barrier by 24.1%, reduced amyloid-beta by 42%, and improved spatial learning by 44% over 56 days in Alzheimer's disease models.
How does Cu(ATSM) work?
It restores P-glycoprotein (P-gp) pump abundance at the blood-brain barrier — the transport proteins that flush amyloid-beta out of the brain. In Alzheimer's these pumps weaken; Cu(ATSM) appears to repair this impairment, allowing the brain's natural waste clearance to resume.
Has Cu(ATSM) been tested in humans?
Yes — for Parkinson's disease and ALS. This existing safety data is its key translational advantage, potentially shortening the path to Alzheimer's trials.
When could this be available for Alzheimer's patients?
No Alzheimer's clinical trial has been announced. If human trials begin, efficacy results would be years away. This is a preclinical finding, not an approved or near-approved treatment.
How is this different from existing drugs like lecanemab?
Lecanemab and donanemab directly remove amyloid plaques via antibodies. Cu(ATSM) works by restoring the brain's own waste-clearance mechanism — a different target and different pathway.
